Associations of adupocutokine and metaboliv hormone level in young people aged 25-44 years with type 2 diabetes mellitus and abdominal obesity
https://doi.org/10.14341/omet12974
Abstract
BACKGROUND: Diabetes mellitus and obesity are two closely related diseases that are a global public health problem. Obesity is characterized by an increase in the volume of adipose tissue and a change in the production and function of adipocytokines, which leads to a violation of the regulation of insulin sensitivity and glucose metabolism, contributing to the development of insulin resistance and diabetic pathology.
AIM: The aim of this study was to evaluate the concentrations of individual adipocytokines and metabolic hormones in patients with DM2 and without diabetes, depending on the presence/absence of abdominal obesity (AO).
MATERIALS AND METHODS: A single-center observational cross-sectional study was conducted. A population subsample of men and women aged 25–44 years was examined. Socio-demographic data were collected, anthropometric measurements were performed. The levels of amylin, C-peptide, ghrelin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 (GLP-1), glucagon, were determined in blood serum by multiplex analysis using a set of reagents Human Metabolic Hormone V3 (USA) and Human Adipokine Panel 1 (USA) on a Luminex MAGPIX flow fluorimeter (USA). interleukin 6, insulin, leptin, monocytic chemotactic factor 1 (MCP-1), pancreatic polypeptide (PP), peptide YY (PYY), tumor necrosis factor alpha (TNF-α), adiponectin, adipsin, lipocalin-2, plasminogen activator inhibitor-1 (PAI-1) and resistin.
RESULTS: The study included 105 people. The main group consisted of 35 people with diabetes mellitus, 11 of them without AO and 24 with AO, the control group consisted of 70 people without diabetes mellitus (35 people with AO and 35 without AO), comparable in gender and age with the main group. In individuals with abdominal obesity, regardless of the presence of type 2 diabetes mellitus, the levels of C-peptide, GLP-1, insulin, leptin and TNF-alpha are higher than in individuals without abdominal obesity. The chance of having diabetes mellitus and AO is associated with an increase in leptin levels (OR=1.367, 95% CI: 1.050–1.779, p=0.020).
CONCLUSION: The results of our study show that the indicators of the adipocytokine profile differ significantly in individuals with the presence/absence of abdominal obesity. According to our data, leptin makes the greatest contribution to the development of SD2 against the background of AO. Further research is needed to identify causal relationships and determine whether treatment that regulates adipocytokine levels can help in personalized approaches to the prevention and treatment of type 2 diabetes mellitus.
About the Authors
E. V. KashtanovaRussian Federation
Elena V. Kashtanova - MD, PhD in biology.
Novosibirsk
Researcher ID: J-4675-2016; Scopus Author ID: 8645249000
Competing Interests:
None
Ya. V. Polonskaya
Russian Federation
Yana V. Polonskaya - MD, PhD in biology.
Novosibirsk
Researcher ID: H-4397-2016; Scopus Author ID: 57216801775
Competing Interests:
None
L. V. Shcherbakova
Russian Federation
Liliya V. Shcherbakova.
Novosibirsk
Researcher ID: ABA-9069-2021; Scopus Author ID: 15030341800
Competing Interests:
None
E. M. Stakhneva
Russian Federation
Ekaterina M. Stakhneva - PhD in biology.
Novosibirsk
Researcher ID: R-1589-2016; Scopus Author ID: 24774022600
Competing Interests:
None
V. S. Shramko
Russian Federation
Viktoriya S. Shramko - MD, PhD.
Novosibirsk
Researcher ID: ABG-9543-2020; Scopus Author ID: 57194556107
Competing Interests:
None
S. V. Mustafina
Russian Federation
Svetlana V. Mustafina - MD, PhD.
Novosibirsk
Competing Interests:
None
A. D. Khudyakova
Russian Federation
Alena D. Khudiakova - MD, PhD.
Novosibirsk
Researcher ID: AAC-7782-2019; Scopus Author ID: 57221943610
Competing Interests:
None
Yu. I. Ragino
Russian Federation
Yulia I. Ragino - MD, PhD, Professor.
Novosibirsk
Researcher ID: E-9498-2015; Scopus Author ID: 6602418274
Competing Interests:
None
References
1. Qadir MI, Ahmed Z. lep Expression and Its Role in Obesity and Type-2 Diabetes. Crit Rev Eukaryot Gene Expr. 2017;27(1):47-51. doi: https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017019386
2. Urbanavitius V, Abaliksta T, Brimas G, et al. Comparison of changes in blood glucose, insulin resistance indices, and adipokine levels in diabetic and nondiabetic subjects with morbid obesity after laparoscopic adjustable gastric banding. Medicina (Kaunas) 2013;49(1):9-14
3. Etemad A, Ramachandran V, Pishva SR, et al. Analysis of Gln223Agr polymorphism of Leptin Receptor Gene in type II diabetic mellitus subjects among Malaysians. Int J Mol Sci. 2013;14(9):19230-44. doi: https://doi.org/10.3390/ijms140919230
4. Isfort M, Stevens SC, Schaffer S, Jong CJ, Wold LE. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev. 2014;19(1):35-48. doi: https://doi.org/10.1007/s10741-013-9377-8
5. Adeghate E, Singh J. Structural changes in the myocardium during diabetes-induced cardiomyopathy. Heart Fail Rev. 2014;19(1):15-23. doi: https://doi.org/10.1007/s10741-013-9388-5
6. Al-Hamodi Z, Al-Habori M, Al-Meeri A, Saif-Ali R. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetol Metab Syndr. 2014;6(1):99. doi: https://doi.org/10.1186/1758-5996-6-99
7. Picu A, Petcu L, §tefan S, et al. Markers of oxidative stress and antioxidant defense in romanian patients with type 2 diabetes mellitus and obesity. Molecules. 2017;22(5):714. doi: https://doi.org/10.3390/molecules22050714
8. Stepien M, Rosniak-Bak K, Paradowski M, et al. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: Preliminary results. MedSciMonit. 2011;17(11):PR13-18. doi: https://doi.org/10.12659/msm.882030
9. Niu M, Xiang L, Liu Y, et al. Adiponectin induced AMP-activated protein kinase impairment mediates insulin resistance in Bama minipig fed high-fat and high-sucrose diet. Asian-Australas J Anim Sci. 2017;30(8):1190-1197. doi: https://doi.org/10.5713/ajas.17.0006
10. Reinehr T, Woelfle J, Wiegand S, et al. Leptin but not adiponectin is related to type 2 diabetes mellitus in obese adolescents. Pediatr Diabetes. 2016;17(4):281-8. doi: https://doi.org/10.1111/pedi.12276
11. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva. 1999;59
12. Bidulescu A, Dinh PC Jr, Sarwary S, et al. Associations of leptin and adiponectin with incident type 2 diabetes and interactions among African Americans: the Jackson heart study. BMC Endocr Disord. 2020;20(1):31. doi: https://doi.org/10.1186/s12902-020-0511-z
13. Ghadge AA, Khaire AA. Leptin as a predictive marker for metabolic syndrome. Cytokine. 2019;121:154735. doi: https://doi.org/10.1016/j.cyto.2019.154735
14. Lee K.W, Shin D. Prospective Associations of Serum Adiponectin, Leptin, and Leptin-Adiponectin Ratio with Incidence of Metabolic Syndrome: The Korean Genome and Epidemiology Study. Int. J. Environ. Res. Public Health. 2020;17:3287. doi: https://doi.org/10.3390/ijerph17093287
15. Smirnova EN, Shulkina SG. Leptin, soluble leptin receptor and the free leptin index in patients with metabolic syndrome. Obesity and metabolism. 2017;14(1):30-34. (in Russ). doi: https://doi.org/10.14341/OMET2017130-34
16. Hansen D, Dendale P, Beelen M, et al. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol. 2010;109(3):397-404. doi: https://doi.org/10.1007/s00421-010-1362-5
17. Chearskul S, Sriwijitkamol A, Kooptiwut S, et al. Cardiometabolic risk in Thai adults with type 2 diabetes mellitus: obese versus non-obese. J Med Assoc Thai. 2015;98(6):528-34
18. Gonzalez N, Moreno-Villegas Z, Gonzalez-Bris A, et al. Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes. Cardiovasc Diabetol. 2017;16(1):44. doi: https://doi.org/10.1186/s12933-017-0528-4
19. Mishra AK, Dubey V, Ghosh AR. Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota. Metabolism. 2016;65(1):48-65. doi: https://doi.org/10.1016/j.metabol.2015.10.008
20. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20 Suppl 1:5-21. doi: https://doi.org/10.1111/dom.13129
21. Opinto G, Natalicchio A, Marchetti P. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity. Arch Physiol Biochem. 2013;119(4):170-8. doi: https://doi.org/10.3109/13813455.2013.812664
22. Stinson SE, Jonsson AE, Lund MAV, et al. Fasting Plasma GLP-1 Is Associated With Overweight/Obesity and Cardiometabolic Risk Factors in Children and Adolescents. J Clin Endocrinol Metab. 2021;106(6):1718-1727. doi: https://doi.org/10.1210/clinem/dgab098
23. Seon MJ, Hwang SY, Son Y, Song J, Kim OY. Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women. Nutrients. 2021;13(3):865. doi: https://doi.org/10.3390/nu13030865
24. Chia CW, Carlson OD, Liu DD, et al. Incretin secretion in humans is under the influence of cannabinoid receptors. Am J Physiol Endocrinol Metab. 2017;313(3):E359-E366. doi: https://doi.org/10.1152/ajpendo.00080.2017
25. Bulgakova SV, Romanchuk NP, Treneva EV. Glyukagonopodobnyj peptid 1, golovnoj mozg, nejrodegenerativnye zabolevaniya: sovremennyj vzglyad // Byulleten' nauki i praktiki. 2020;6(4):153-172. (in Russ). doi: https://doi.org/10.33619/2414-2948/53/19
Review
For citations:
Kashtanova E.V., Polonskaya Ya.V., Shcherbakova L.V., Stakhneva E.M., Shramko V.S., Mustafina S.V., Khudyakova A.D., Ragino Yu.I. Associations of adupocutokine and metaboliv hormone level in young people aged 25-44 years with type 2 diabetes mellitus and abdominal obesity. Obesity and metabolism. 2024;21(1):14-23. (In Russ.) https://doi.org/10.14341/omet12974

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).